Active not recruiting × Vulvar Neoplasms × Dermatologic × Clear all
NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled